Home > Publications Database > Hippocampal vascularization is associated with greater efficiency during a remote real world wayfinding training in older adults > print

001     283093
005     20251230140445.0
024 7 _ |a 10.1002/alz70863_110578
|2 doi
024 7 _ |a pmid:41433357
|2 pmid
024 7 _ |a pmc:PMC12725357
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2025-01500
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Marquardt, Jonas
|0 P:(DE-2719)9001692
|b 0
|e First author
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Hippocampal vascularization is associated with greater efficiency during a remote real world wayfinding training in older adults
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767099684_6288
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Alzheimer's Disease (AD) pathology accumulates early in the medial temporal lobe (MTL), crucial for spatial navigation. As spatial navigation is among the first cognitive functions affected by AD, it may benefit from targeted behavioral interventions. We investigated the potential of a novel smartphone-assisted real-world wayfinding training, tailored for healthy older adults, to improve their spatial abilities and explored associations with hippocampal vascularization and AD biomarkers.38 cognitively healthy older adults (62-84 years; 18 females) participated in a 3-week navigation training, using our smartphone application 'Explore' (Figure 1). Training involved finding several locations displayed on a map in the medical campus area of Magdeburg, Germany, while GPS data were recorded. Pre- and post-training, participants underwent fMRI, performed a pointing task in a virtual campus version, and completed the VWLT. At pre-assessment, AD pathology was characterized by plasma sampling (Abeta1-42/1-40, Ptau217) and [18F]PI-2620 PET in a subsample. Hippocampal vascularization was assessed by 7T angiography. Performance in the virtual pointing task and a map drawing test was compared to a control group (n = 20) who performed a walking task of equal length without a navigational component. Additionally, changes in different mobile wayfinding performance indicators and their associations with AD biomarkers and hippocampal vascularization (i.e., mean distance of hippocampus to surrounding vessels) were examined.Performance in the pointing task and map drawing, but not in the VWLT (p = .321), significantly improved due to the training (all p <.001; Figure 2A C). The control group showed no improvements in navigation. Training benefits were also evident in the mobile data (all p ≤.017; Figure 3A-E). Better wayfinding efficiency was associated with less vessel distance to hippocampus, r=.44, p = .012, and the number of orientation stops was negatively related to pTau217, r=-.38, p = .019 (Figure 3F).We provide evidence that a remotely administered real-world wayfinding training enhances wayfinding abilities and improves spatial memory in older adults. Importantly, hippocampal vascularization may benefit wayfinding efficiency. Higher pTau217 was related to fewer orientation stops during navigation. As a next step, potential mediating effects between vascularization and AD pathology on wayfinding performance will be investigated.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Hippocampus: diagnostic imaging
|2 MeSH
650 _ 2 |a Hippocampus: blood supply
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease
|2 MeSH
650 _ 2 |a Spatial Navigation: physiology
|2 MeSH
650 _ 2 |a Smartphone
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: blood
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Mobile Applications
|2 MeSH
650 _ 2 |a Dementia
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
700 1 _ |a Vockert, Niklas
|0 P:(DE-2719)9000804
|b 1
700 1 _ |a Behrenbruch, Niklas
|0 P:(DE-2719)9002133
|b 2
700 1 _ |a Schumann-Werner, Beate
|0 P:(DE-2719)9002320
|b 3
700 1 _ |a Hochkeppler, Anne
|0 P:(DE-2719)2812346
|b 4
700 1 _ |a Buechel, Anna-Therese
|0 P:(DE-2719)9001800
|b 5
700 1 _ |a Molloy, Eóin N.
|0 P:(DE-2719)9002180
|b 6
700 1 _ |a Schwarck, Svenja
|0 P:(DE-2719)9000379
|b 7
700 1 _ |a Fischer, Larissa
|0 P:(DE-2719)9002356
|b 8
700 1 _ |a Incesoy, Enise I
|0 P:(DE-2719)9001517
|b 9
700 1 _ |a Garcia-Garcia, Berta
|0 P:(DE-2719)2812734
|b 10
700 1 _ |a Mattern, Hendrik
|0 P:(DE-2719)9002178
|b 11
700 1 _ |a Marcos Morgado, Barbara
|0 P:(DE-2719)9003591
|b 12
700 1 _ |a Esselmann, Hermann
|b 13
700 1 _ |a Stephens, Andrew W
|b 14
700 1 _ |a Schildan, Andreas
|b 15
700 1 _ |a Barthel, Henryk
|b 16
700 1 _ |a Sabri, Osama
|0 P:(DE-2719)2814810
|b 17
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 18
700 1 _ |a Kreissl, Michael C
|0 P:(DE-2719)2812799
|b 19
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 20
700 1 _ |a Kuehn, Esther
|0 P:(DE-2719)9001179
|b 21
700 1 _ |a Schreiber, Stefanie
|0 P:(DE-2719)2812631
|b 22
700 1 _ |a Maass, Anne
|0 P:(DE-2719)2811815
|b 23
700 1 _ |a Diersch, Nadine
|0 P:(DE-2719)2811077
|b 24
|e Last author
773 _ _ |a 10.1002/alz70863_110578
|g Vol. 21 Suppl 9, no. Suppl 9, p. e110578
|0 PERI:(DE-600)2201940-6
|n Suppl 9
|p e110578
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283093/files/DZNE-2025-1500.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283093/files/DZNE-2025-1500.pdf?subformat=pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001692
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000804
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002133
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9002320
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812346
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001800
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9002180
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9000379
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9002356
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001517
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812734
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9002178
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)9003591
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 17
|6 P:(DE-2719)2814810
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2812799
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)9001179
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2812631
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2811815
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2811077
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1311001
|k AG Maaß
|l Multimodal Neuroimaging
|x 0
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 1
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 2
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 3
920 1 _ |0 I:(DE-2719)1340016
|k Core MR PET
|l Core MR PET
|x 4
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 5
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1311001
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1310010
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1340016
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21